Health officials have issued a crucial warning to pregnant women, advising them to avoid using weight-loss injections known as “skinny jabs.” The Medicines and Healthcare products Regulatory Agency (MHRA) emphasises the potential risks these injections pose to both expectant mothers and their unborn children. This advisory highlights the growing concern over the use of such treatments during pregnancy and the need for careful consideration of their potential side effects.
The MHRA’s guidance comes amid increasing popularity of weight-loss injections, which have been marketed as a quick solution for shedding pounds. These injections, often containing the active ingredient semaglutide, mimic a hormone that targets areas of the brain regulating appetite. While they have shown effectiveness in weight management for non-pregnant individuals, their safety profile during pregnancy remains a significant concern.
Timing of the Advisory
The MHRA released this advisory on 5 June 2025, in response to rising inquiries from healthcare professionals and the public. The advice aims to mitigate any adverse health outcomes resulting from the use of these injections during pregnancy. This timing coincides with an increasing trend of self-administered weight-loss treatments, prompting health officials to act decisively to protect vulnerable populations, including pregnant women.
The advisory specifically targets women who are currently pregnant or planning to conceive. It also urges healthcare providers to convey the importance of avoiding these injections and to discuss alternative weight management strategies that are safe for pregnancy.
Understanding the Risks
Weight-loss injections like the popular semaglutide-based treatments have not been thoroughly tested for safety in pregnant women. The MHRA warns that the lack of robust clinical data presents a risk that cannot be ignored. Dr. Sarah Jones, a leading expert in maternal health, explains, “The physiological changes during pregnancy make it difficult to predict how these injections might affect both the mother and the developing fetus.”
While weight management is a common concern for many women, especially during pregnancy, experts stress the importance of prioritising the health of both mother and child. The potential for adverse effects, such as developmental issues or complications during childbirth, underscores the need for caution.
The Role of Effective Contraception
In addition to avoiding these injections during pregnancy, women are advised to use effective contraception if they are taking “skinny jabs.” The MHRA highlights that unintended pregnancies while on these treatments could lead to unforeseen complications. Dr. Emily Roberts, a reproductive health specialist, notes, “It’s crucial for women to understand the importance of reliable contraception when considering any medication that could impact pregnancy.”
The MHRA’s recommendation aligns with existing guidelines that stress the need for comprehensive family planning and informed decision-making when using pharmaceuticals that affect hormonal balance.
Expert Insights and Alternatives
Healthcare professionals are encouraged to discuss alternative weight management strategies with their patients. Dr. Michael Thompson, a nutritionist, suggests, “Balanced diets and regular physical activity remain the safest and most effective methods for managing weight, especially during pregnancy.” These lifestyle changes not only promote healthy weight but also contribute to overall well-being for both mother and child.
The MHRA also recommends consulting with healthcare providers to develop personalised plans that account for individual health needs and pregnancy goals. This approach ensures that women receive the support necessary to maintain a healthy pregnancy without resorting to potentially harmful treatments.
Looking Ahead
As the use of weight-loss injections continues to rise, the MHRA’s advisory serves as a timely reminder of the importance of prioritising safety, particularly for pregnant women. The agency’s guidance underscores the need for ongoing research to better understand the implications of such treatments during pregnancy.
Future efforts will likely focus on educating both healthcare providers and the public about the risks associated with weight-loss injections and the importance of safe weight management practices. By fostering informed decision-making, health officials hope to minimise potential risks and promote a healthier future for mothers and their children.
The MHRA’s advisory highlights the critical role of informed healthcare choices and the need for vigilance when considering treatments during pregnancy. As more women seek weight management solutions, the emphasis remains on ensuring that these choices do not compromise the health and safety of the most vulnerable.
